Masimo (NASDAQ:MASI – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.810-0.860 for the period, compared to the consensus EPS estimate of 0.830. The company issued revenue guidance of $495.0 million-$515.0 million, compared to the consensus revenue estimate of $502.2 million. Masimo also updated its Q3 guidance to $0.81-0.86 EPS.
Masimo Trading Up 6.0 %
Masimo stock opened at $133.77 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15. The firm’s 50 day moving average price is $116.15 and its 200-day moving average price is $124.92. Masimo has a 1 year low of $75.22 and a 1 year high of $153.93. The stock has a market cap of $7.11 billion, a P/E ratio of 91.00 and a beta of 0.98.
Masimo (NASDAQ:MASI – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The company had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. During the same period in the previous year, the firm posted $0.62 EPS. Masimo’s revenue for the quarter was up 9.0% compared to the same quarter last year. On average, equities analysts predict that Masimo will post 3.87 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Masimo
Masimo Company Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Recommended Stories
- Five stocks we like better than Masimo
- EV Stocks and How to Profit from Them
- Analysts Weigh In: How Will Lower Rates Impact Carvana Stock?
- What are earnings reports?
- Why AutoZone Stock Could Be Your Next Top Performer
- What Does Downgrade Mean in Investing?
- Should You Invest in Treasury Bills?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.